INCY received $50 million milestones from each of Lilly and Novartis for starting phase III trials.
Sorry, should have been more specific. I'm thinking in terms of more apples-to-apples small-cap biotech comparisons to THLD (i.e., sub-$500M market cap).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.